• Licensing and supervision
    • Brexit
    • Licensing of medicines
    • Authorisation procedures
    • Company authorisations and registrations
    • Supervision and inspection
    • Clinical trials
    • How to evaluate evidence of the efficacy of medicines
    • Evaluation of reviews
    • Report suspected illegal activities
    • Falsified medicines
    • Compassionate use
    • Medicine or not
    • Export certificates
    • Fees
    • Name/address changes
    • Professional relationships and financial support, applicable to healthcare professionals and specialists
    • Relationships with and financial support from companies
    • Medicinal Products Committee
    • Publications
  • Side effects and product information
    • Side effects of medicines
    • Additional monitoring
    • News on pharmacovigilance
    • Biological and biosimilar medicinal products
    • Safety updates
    • Post Authorisation Safety Study
    • Direct Healthcare Professional Communication
    • Adverse events
    • Drug interaction
    • Pharmacovigilance Council
    • Find medicines
    • Publications
  • Reimbursement and prices
    • General reimbursement
    • Individual reimbursement
    • Reimbursement thresholds
    • Medicines bought in another EU/EEA country
    • Reimbursement Committee
    • The EU HTA regulation
    • Prices of medicines
    • Product numbers
    • Central Reimbursement Register
    • Reimbursable nutritional products
    • Publications
  • Pharmacies and sale of medicines
    • Pharmacies
    • Sale outside pharmacies
    • Over-the-counter medicines
    • Substitution
    • Medicines imported from abroad
    • Buying and selling medicines online
    • Sale of medicines or food supplements online
    • Doctors buying medicines for use in their own practices
    • Report suspected illegal sale of medicines
    • Prescriptions from another country
    • Publications
  • Medical devices
    • Incident reporting
    • Interruption or discontinuation of the supply of medical devices
    • New regulations
    • New Tech – new technological possibilities and medical devices
    • Development of medical devices
    • Regulatory advice for medical device companies
    • CE marking
    • Notified bodies
    • Registration and marketing
    • Clinical investigations
    • Performance studies of in vitro diagnostic medical devices (IVDs)
    • Certificates of Free Sale
    • Legislation and guidance
    • Publications
  • Special product areas
    • Veterinary medicines
    • Natural medicinal products and vitamin and mineral products
    • Euphoriant substances
    • Medical gases
    • Radiopharmaceuticals
    • Medicines affecting the ability to drive
    • Medicinal cannabis
    • Regulation of innovative medicinal products including ATMP
  • About us
    • Mission, vision and strategy
    • Contact
    • Organisation
    • Data Analytics Centre (DAC)
    • Whistleblowing scheme of the Danish Medicines Agency
    • The Danish Medicines Agency funding
    • Management of conflicts of interest
    • Transparency in the Danish Medicines Agency
    • Data protection policy
    • Targets and tasks
    • International collaboration
    • Jobs
    • Digital services
    • About this site
    • Social media
    • Design
    • Campaigns
    • Copyright and logo
    • Cookies
    • Publications
    • Sitemap
  • News
    • Subscribe to news
    • Edit subscription
    • Unsubscribe
    • News categories
    • Themes
    • RSS Feed
  • Publications
    • Order publications
    • 2025
    • 2024
    • 2023
    • 2022
    • 2020
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
    • 2014
    • 2013
    • 2012
    • 2011
    • 2010
    • 2009
    • 2008
    • 2007
    • 2006
Go to main content
  • News
  • About us
  • Contact us
  • Publications
  • Cookies
  • Licensing and supervision
    • Brexit
    • Licensing of medicines
    • Authorisation procedures
    • Company authorisations and registrations
    • Supervision and inspection
    • Clinical trials
    • How to evaluate evidence of the efficacy of medicines
    • Evaluation of reviews
    • Report suspected illegal activities
    • Falsified medicines
    • Compassionate use
    • Medicine or not
    • Export certificates
    • Fees
    • Name/address changes
    • Professional relationships and financial support, applicable to healthcare professionals and specialists
    • Relationships with and financial support from companies
    • Medicinal Products Committee
    • Publications
  • Side effects and product information
    • Side effects of medicines
    • Additional monitoring
    • News on pharmacovigilance
    • Biological and biosimilar medicinal products
    • Safety updates
    • Post Authorisation Safety Study
    • Direct Healthcare Professional Communication
    • Adverse events
    • Drug interaction
    • Pharmacovigilance Council
    • Find medicines
    • Publications
  • Reimbursement and prices
    • General reimbursement
    • Individual reimbursement
    • Reimbursement thresholds
    • Medicines bought in another EU/EEA country
    • Reimbursement Committee
    • The EU HTA regulation
    • Prices of medicines
    • Product numbers
    • Central Reimbursement Register
    • Reimbursable nutritional products
    • Publications
  • Pharmacies and sale of medicines
    • Pharmacies
    • Sale outside pharmacies
    • Over-the-counter medicines
    • Substitution
    • Medicines imported from abroad
    • Buying and selling medicines online
    • Sale of medicines or food supplements online
    • Doctors buying medicines for use in their own practices
    • Report suspected illegal sale of medicines
    • Prescriptions from another country
    • Publications
  • Medical devices
    • Incident reporting
    • Interruption or discontinuation of the supply of medical devices
    • New regulations
    • New Tech – new technological possibilities and medical devices
    • Development of medical devices
    • Regulatory advice for medical device companies
    • CE marking
    • Notified bodies
    • Registration and marketing
    • Clinical investigations
    • Performance studies of in vitro diagnostic medical devices (IVDs)
    • Certificates of Free Sale
    • Legislation and guidance
    • Publications
  • Special product areas
    • Veterinary medicines
    • Natural medicinal products and vitamin and mineral products
    • Euphoriant substances
    • Medical gases
    • Radiopharmaceuticals
    • Medicines affecting the ability to drive
    • Medicinal cannabis
    • Regulation of innovative medicinal products including ATMP
2017
News / 2017
News

You must accept marketing cookies to share the page by mail

Update consent

Share by mail

Verify you are a human

...

  • New executive order raises fees in the area of the Danish Medicines Agency

    | 03 May 2022 |

    Higher fees become payable for medicinal products and pharmaceutical companies as a result of a new executive order entering into force on 1 May 2022. The last time the fees were adjusted was in 2017.

All items (440)

  • Time

    • 2025 (17)
    • 2024 (26)
    • 2023 (24)
    • 2022 (20)
      • December (6)
      • November (1)
      • October (2)
      • August (2)
      • July (2)
      • June (1)
      • May (1)
      • April (2)
      • March (1)
      • February (1)
      • January (1)
    • 2021 (44)
    • 2020 (62)
    • 2019 (20)
    • 2018 (37)
    • 2017 (48)
    • 2016 (43)
    • 2013 (3)
    • 2012 (11)
    • 2011 (13)
    • 2010 (9)
    • 2009 (14)
    • 2008 (7)
    • 2007 (3)
    • 2006 (10)
footer-logo

Danish Medicines Agency

Axel Heides Gade 1

2300 København S

Email: dkma@dkma.dk


The Danish Medicines Agency is part of the
Ministry of Interior and Health.

Contact the Danish Medicines Agency

+45 44 88 95 95 (9am - 3pm)

Follow us

  • facebook logo
  • LinkedIn
  • RSS

CVR-nr. 37 05 24 85

EAN 5798 000 36 33 66

Privacy policy Cookie policy